Clene Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2024. Clene is a clinical-stage pharmaceutical company developing nanotechnology-based drug candidates, primarily for ALS, multiple sclerosis (MS), and Parkinson’s disease. It has no approved drugs and reported only dietary-supplement revenue.
Financial performance and position
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0.073 | $0.107 |
| Cost of revenue / gross profit | $0.016 / $0.057 | $0.005 / $0.102 |
| Gross margin | Approximately 78% | Approximately 95% |
| Research and development expense | $5.869 | $7.395 |
| General and administrative expense | $3.420 | $3.439 |
| Operating loss | $(9.232) | $(10.732) |
| Net loss | $(11.080) | $(11.770) |
| Net loss per share, basic and diluted | $(0.09) | $(0.15) |
| Cash used in operating activities | $(7.082) | $(9.218) |
- Liquidity: At March 31, cash and cash equivalents were $21.732 million and marketable securities were $6.178 million, totaling $27.910 million, compared with $35.000 million at December 31, 2023. Current assets were $32.111 million and current liabilities $26.185 million.
- Debt: Balance-sheet carrying amounts were approximately $16.8 million of notes payable and $10.3 million of convertible notes payable. About $20.0 million was classified as current. The Avenue loan bears a 15.10% rate and includes a $5.0 million minimum unrestricted-cash covenant; the company reported compliance.
- Equity and dilution: Stockholders’ equity was $4.264 million, down from $13.390 million at year-end. There were 128.434 million common shares outstanding at quarter-end. A further 105.432 million shares were underlying outstanding warrants, subject to their terms and exercise conditions.
Material changes versus the prior comparable period
- Revenue declined 32%, primarily due to the timing of 4Life purchases of dietary supplements; substantially all revenue was related-party product and royalty revenue.
- R&D expense declined 21%, principally reflecting completion of blinded periods in clinical trials and lower CNM-ZnAg spending. Lower trial costs were partly offset by ALS expanded-access activity, regulatory work, and personnel costs.
- Operating loss narrowed 14% and net loss narrowed 6%. However, other expense increased to $1.848 million from $1.038 million, including a $1.309 million noncash loss from the change in fair value of warrant liabilities and higher interest expense.
- Operating cash use improved to $7.082 million from $9.218 million. Cash and marketable securities nevertheless fell by approximately $7.1 million from year-end.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that available resources are not expected to sustain current operations or meet obligations over the next 12 months without additional financing. The filing concludes substantial doubt about the company’s ability to continue as a going concern is not alleviated by its plans. The company is considering equity or debt financing, licensing or collaborations, and use of financing facilities, while also reducing or delaying programs and eliminating some positions.
- Funding and obligations: Management identifies $21.9 million of principal and interest payments on notes payable, approximately $1.1 million of operating lease payments and $0.2 million of capital-expenditure commitments over the next 12 months. The Avenue loan may be accelerated upon specified defaults, including failure to maintain the cash minimum.
- Clinical plans: Clene was planning an international Phase 3 ALS trial, RESTORE-ALS, for the second half of 2024, contingent on funding. It planned further FDA engagement by mid-2024 on clinical and biomarker evidence; the filing says timing or ability to submit an NDA is uncertain. The company expected REPAIR-MS enrollment to conclude in the first half of 2024 and topline results by year-end, and anticipated an FDA end-of-Phase-2 meeting in the second half of 2024.
- Grant support: A subsequent-event disclosure describes an NIH expanded-access subaward of up to $7.3 million for eligible ALS program expenses through August 2024, within potential subawards to Clene of up to $30.9 million from a $45.1 million total award. Reimbursement depends on qualifying expenses and grant terms; future subawards require further agreements. The company said it had incurred $3.1 million of qualifying expenses to date to request reimbursement.
- Potential expense changes: Management anticipates R&D spending could increase as programs advance toward Phase 3. Commercial-readiness and administrative spending may also rise if an NDA pathway advances; if not, the company expects further cost reductions.
- Accounting and controls: The $1.309 million warrant-liability fair-value loss was noncash and model-sensitive. Disclosure controls were deemed ineffective because of material weaknesses involving the control environment, reconciliations and journal-entry review, segregation of duties, and IT general controls. Remediation is ongoing.
- Other matters: There were no material pending legal proceedings reported. Potential National Multiple Sclerosis Society grant repayments depend on specified future commercial, financing, or licensing events; no liability was recorded because management assessed the events as less than probable. The filing reports no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether Clene secures financing in time to fund operations, clinical programs, and debt obligations, and whether any financing materially dilutes shareholders.
- Current cash runway and the status and terms of the ATM facility, including the May 8, 2024 prospectus supplement for up to $12.3 million of future sales.
- Whether the NIH subaward and any future subawards are finalized, eligible expenses are reimbursed, and funding is sufficient to support the ALS expanded-access program.
- Progress and funding for RESTORE-ALS, FDA feedback on the proposed evidence and NDA path, and reported MS trial results as they are independently evaluated and updated.
- Changes in debt balances, maturity and covenant compliance, warrant-related liabilities, and potential dilution from the substantial warrant and option overhang.
- Progress in remediating the disclosed material weaknesses and whether management later reports effective disclosure controls.